Upstream Bio, Inc. (UPB) Cash Flow Statement
Upstream Bio, Inc. (UPB) generated -$136.3M of operating cash flow over the twelve months to 2026-06-30, spent $118000 on capital expenditure and had free cash flow of -$136.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
UPBUpstream Bio, Inc.Follow UPB — free
—
Price chart with a free account
- Market cap
- 150.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -59.2 | -133.3 | -136.3 | |
| Capital expenditure | 0.5 | 0.2 | -0.1 | |
| Free cash flow | -59.7 | -133.4 | -136.5 | |
| Stock-based compensation | 6.0 | 10.3 | — |
USD millions · SEC XBRL
Upstream Bio, Inc. — questions
- What is Upstream Bio, Inc.'s operating cash flow?
- -$136.3M over the twelve months to 2026-06-30.
- How much does Upstream Bio, Inc. spend on capital expenditure?
- $118000 over the twelve months to 2026-06-30.
- What is Upstream Bio, Inc.'s free cash flow?
- -$136.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Upstream Bio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.